Realistic Lenalidomide Dose Adjustment Strategy for Transplant-Ineligible Elderly Patients with Relapsed/Refractory Multiple Myeloma: Japanese Real-World Experience
Clicks: 210
ID: 274757
2017
Article Quality & Performance Metrics
Overall Quality
Improving Quality
0.0
/100
Combines engagement data with AI-assessed academic quality
Reader Engagement
Emerging Content
3.0
/100
10 views
10 readers
Trending
AI Quality Assessment
Not analyzed
Abstract
Lenalidomide is an immunomodulatory drug administered orally in the treatment of multiple myeloma. Some elderly patients require a reduced lenalidomide dose because of comorbidities and/or adverse events. This study investigated the actual dose of lenalidomide ...
| Reference Key |
nomura2017actarealistic
Use this key to autocite in the manuscript while using
SciMatic Manuscript Manager or Thesis Manager
|
|---|---|
| Authors | Aya Nakaya, Shinya Fujita, Atsushi Satake, Takahisa Nakanishi, Yoshiko Azuma, Yukie Tsubokura, Masaaki Hotta, Hideaki Yoshimura, Kazuyoshi Ishii, Tomoki Ito, Shosaku Nomura;Aya Nakaya;Shinya Fujita;Atsushi Satake;Takahisa Nakanishi;Yoshiko Azuma;Yukie Tsubokura;Masaaki Hotta;Hideaki Yoshimura;Kazuyoshi Ishii;Tomoki Ito;Shosaku Nomura; |
| Journal | acta haematologica |
| Year | 2017 |
| DOI |
10.1159/000477792
|
| URL | |
| Keywords |
|
Citations
No citations found. To add a citation, contact the admin at info@scimatic.org
Comments
No comments yet. Be the first to comment on this article.